Slide 1: Cover letter to stock exchanges: Q3 FY25 Earnings Presentation
12th February, 2025 Corporate Relationship Department Manager – Listing M/s. BSE Ltd M/s. National Stock Exchange of India Ltd Dalal Street, For, “Exchange Plaza”, Bandra Kurla Complex Mumbai 400001 Bandra East, Mumbai 400051 Scrip Code: 524816 Scrip Code: NATCOPHARM Dear Sir / Madam, Sub: - Q3 FY25
Slide 2: Earnings Presentation Q3 FY25
Earnings Presentation Q3 FY25
Slide 3: Disclaimer
Disclaimer THIS PRESENTATION (PRESENTATION) IS NOT AN OFFER TO SELL ANY SECURITIES OR A SOLICITATION TO BUY ANY SECURITIES OF NATCO PHARMA LIMITED OR ITS SUBSIDIARIES OR JOINT VENTURES (TOGETHER, THE “COMPANY”). The material that follows is a Presentation of general background information about the
Slide 4: Q3FY25 – Key Business & Consolidated Financial Highlights
Q3FY25 – Key Business & Consolidated Financial Highlights Total Revenue stood at INR 6,511 Mn| Pharma Export Formulations at INR 2,858 Mn | Domestic Formulations Revenue at INR 961 Mn Earnings Before Interest Tax Depreciation and Amortization stood at INR 2,151 Mn and EBITDA Margin at 33% for Q3 FY2
Slide 5: Q3FY25 – Quarterly Performance
Q3FY25 – Quarterly Performance Revenue Breakup (INR Mn) Revenue Breakup (%) – Q3FY25 Revenue Division Q3FY25 Q3FY24 Q2FY25 29% API Revenue 666 463 496 44% Formulation Formulation – Exports (incl profit share, 10% license income, export service income & 2,858 6,056 12,113 2% Subsidiaries) Export Form
Slide 6: Consolidated Profit & Loss Statement
Consolidated Profit & Loss Statement Profit & Loss Statement (INR Mn) Q3FY25 Q3FY24 Q2FY25 Total Revenue 6,511 7,956 14,349 Total Expenses (before finance cost and depreciation) 4,360 4,905 5,668 Earnings before interest, tax, depreciation and amortization (EBITDA) 2,151 3,051 8,681 EBITDA Margin* (
Slide 7: Key Product Pipeline - USA
Key Product Pipeline - USA 28 Para IVs in the pipeline 13 Approved (either tentative or fully) Key Sole FTFs (Para IV) in the pipeline Key Para IV (shared FTFs) products in the pipeline Therapeutic Therapeutic Key Brand Molecule Segment / Primary Key Brand Molecule Segment / Primary Indication Indic
Slide 8: Earnings Call Details – Q3FY25
Earnings Call Details – Q3FY25 The Earnings call to discuss the operational and financial performance of the company with Mr. Rajeev Nannapaneni, Vice Chairman and Chief Executive Officer and Mr. Rajesh Chebiyam, Executive Vice President, Crop Health Sciences are as below: Details of the Earnings ca
Slide 9: Thank You
Thank You Contact: Rajeev Menon – Investor Relations Rajesh Chebiyam – EVP, Crop Health Sciences r.menon@natcopharma.co.in / Rajesh.Chebiyam@natcopharma.co.in 040-23546208/ Ext: 323 https://twitter.com/pharma_natco https://www.linkedin.com/company/natcopharma